Benzinga | Jun 11, 2021 08:29AM EDT

Goldman Sachs Maintains Buy on Vertex Pharmaceuticals, Lowers Price Target to $307

Goldman Sachs maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and lowers the price target from $358 to $307.